In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
DVA's strength in its kidney care business raises optimism about the stock.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Investors target stocks that have been on a bullish run lately. Stocks like THC, SLVM, DVA, NCLH and IAG are seeing price strength, and the momentum is likely to continue.
DaVita HealthCare (DVA) closed the most recent trading day at $163.08, moving +0.51% from the previous trading session.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.